The global neurological biomarkers market is estimated to reach a valuation of US$ 8 billion in 2023. As per Future Market Insights (FMI) analysis, the neurological biomarkers market size is expected to surpass US$ 12.5 billion in the next decade. Between 2023 and 2033, the market has been forecast to register a 4.6% CAGR.
In their healthcare business, key players have a central platform for storing, managing, and analyzing biomarker and multi-omics data. The Human Genome Project's emergence provided researchers with new molecular tools for gene identification and gene expression. It allowed researchers to detect genetic flaws linked to complicated disorders, including common neurological ailments, ushering in a new era of study.
Customized antibodies and assays are developed by key players to measure unique clinical biomarkers in a wide range of neurodegenerative disorders and conditions, including Alzheimer's disease, Parkinson's disease, and traumatic brain injury. Their tests allow for early identification of symptoms before they arise, delivering vital information from the medication research phase to clinical practice, therefore improving the lives of patients. This development is expected to boost the market further.
For instance, the 'TaqMan Gene Expression Assays enable researchers to employ real-time PCR to analyze how gene expression changes in samples collected from a person suffering from a complicated ailment. Furthermore, TaqMan Assays can be used in in-vitro investigations that focus on a specific genetic or environmental component that is hypothesized to be implicated in complex disease.
Cerebrospinal Fluid (CSF) biomarkers and neurofilament proteins, according to experts, should be stable during long-term preservation. However, there are few studies and some evidence that freezing and thawing might cause structural alterations in CSF samples. Increasing CSF sample storage might result in experimental data that can be used to solve this topic. Such studies provide opportunities for market players and act as propellers for the market.
All of the research conducted by significant firms is evidence-based, and patients are managed using a test based on facts rather than subjective interpretation. Furthermore, they strive for safe therapies by limiting needless CT scan radiation exposure. Most key players have extensive experience in executing and cooperating on clinical research. They feel that collaboration is critical in developing novel biomarkers and therapies for the brain. Hence, key players engage in collaborative work and aid the market.
Moreover, they also allow their customers to collaborate by contacting them to handle brain damage and neurological illnesses. In addition, they provide access to a constantly expanding library of thousands of highly-curated disease-relevant experiments, including immunological, neurological, metabolic, and cardiovascular illnesses, with a special focus on expression studies, to speed predictive biomarkers and therapeutic target development, thus helping market growth.
| Attributes | Details |
|---|---|
| Neurological Biomarkers Market HCAGR (2017 to 2022) | 5.2% |
| Neurological Biomarkers Market CAGR (2023 to 2033) | 4.6% |
| Market Size for Neurological Biomarkers (2023) | US$ 8 billion |
| Market Size for Neurological Biomarkers (2033) | US$ 12.5 billion |
| Market Size for Neurological Biomarkers - Absolute Dollar Growth | US$ 4.6 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The statistics accumulated by Future Market Insights reveal the global forum of neurological biomarkers, which has witnessed an unprecedented surge over the past few years. The key providers in the market are in conjunction with the increasing demand for neurological biomarkers. There has been a gradual rise from a CAGR of 5.2% registered during the period of 2017 to 2022 and is likely to decrease at an adequate 4.6% in the forecast period.
Complications in the basic understanding of the molecular signatures of biological processes, as well as the neglect of treatment of neurological disorders, may slightly decline the market growth during the forecast period. On the contrary, spreading awareness regarding the benefits of predictive biomarkers may create several market opportunities for key clinicians.
Alzheimer's Disease - By Application Type
By application type, the market is segmented into Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, depression, multiple sclerosis, and spinal muscular atrophy. It has been studied by the analysts at Future Market Insights that the Alzheimer's disease segment is estimated to hold a major market share of 5.2% through the forecast period.
The vital elements determining the momentum of this segment are:
Pharma & Biotech Companies - By End User Type
By end-user type, the market is segmented into research organizations, pharma & biotech companies, and clinical diagnostics. It has been studied by the analysts at Future Market Insights that the pharma & biotech companies segment is estimated to hold the largest market share through the forecast period.
Recent biomarker breakthroughs, such as biomarker signatures, are making neurological illnesses more curable. As a result, non-invasive diagnostics, faster medication development, and earlier diagnosis are now possible. In addition, key players are conducting clinical trials and biomarker research and development (R&D) to provide more precise findings for neurological illnesses, which is likely to increase demand for neurological biomarkers throughout the projected period.
The need for verifying and finding biomarkers in big populations is enormous. This strategy is being used in the research process, which increases the likelihood of the neurological biomarkers market growing rapidly in the next years. Furthermore, neuropathologists are expected to determine the nomination and delineation of suitable treatment regimens as new and fresh neuroscience biomarkers are introduced.
Precision medicine, also known as customized medicine, has been identified as one of the most promising techniques for treating a variety of disorders. The increasing frequency of the brain and other nervous system tumors is one of the primary reasons driving the market growth. It is becoming more used as a diagnostic technique, assisting in the identification of certain biological markers.
Principal Consultant
| Country | United States |
|---|---|
| CAGR (2023 to 2033) | 3.9% |
| HCAGR (2017 to 2022) | 4.3% |
| Country | United Kingdom |
|---|---|
| CAGR (2023 to 2033) | 3.5% |
| HCAGR (2017 to 2022) | 4.3% |
| Country | China |
|---|---|
| CAGR (2023 to 2033) | 5.9% |
| HCAGR (2017 to 2022) | 6.3% |
| Country | Japan |
|---|---|
| CAGR (2023 to 2033) | 5.3% |
| HCAGR (2017 to 2022) | 6% |
| Country | India |
|---|---|
| CAGR (2023 to 2033) | 6.1% |
| HCAGR (2017 to 2022) | 7.3% |
| Attributes | Details |
|---|---|
| USA Market Size (2033) | US$ 3.9 billion |
| USA Market Absolute Dollar Growth (US$ million/billion) | US$ 1.2 billion |
North America is one of the leading neurological biomarkers markets. The USA is the most lucrative market in the region, with a revenue share of 3.9%. The value of the smart home devices market in the USA is estimated to reach a high of US$ 3.9 billion by the year 2033. The dominance of the country is attributed in part to its relatively high illness burden, adoption of biomarkers for diagnostic, therapeutic development, and prognostic reasons, and a boost in research funding.
The global cost of dementia was $818 billion in 2015, and it is anticipated to reach $2 Tn by 2030, according to the WHO. Key stakeholders in the United States are delivering an interactive teaching course that includes insights from world-renowned specialists on the clinical utility of standardized CSF testing to enable a fast diagnosis of Alzheimer's disease.
To speed clinical development projects, top scientists and industry-leading laboratories drive the creation of more advanced biomarker strategies, as well as specialized tests and on-target protocol assistance. Furthermore, prominent doctors claim to have extensive neurodegeneration biomarker experience to assist in making decisions. They have a strategic focus on neurodegeneration, neuroinflammation, traumatic brain injuries (TBI), and multiple sclerosis (M.S.), and they collaborate with a fast-developing network of university researchers, pharmaceutical, and biotech partners to enhance head health research.
Germany is a market with several market opportunities and a favorable revenue share. Key players in Germany provide research facilities that target all aspects of neurodegenerative illnesses (such as Alzheimer's, Parkinson's, and Amyotrophic lateral sclerosis) in order to create innovative preventive, treatment, and healthcare techniques. On a national and global scale, they work closely with universities, university hospitals, and other research institutes.
Key players strive to produce so-called functional biomarkers based on neural network activity utilizing artificial intelligence and unique mathematical techniques. These biomarkers are supposed to disclose whether the network is functioning properly or not, as well as if a certain medicine changes this state, which ultimately assists in the identification of potential drugs. Moreover, driven by a passion for promoting human health for all, they are establishing a network of discovery, connecting scientists, and exchanging thoughts, ideas, and knowledge in order to advance neuroscience research.
| Attributes | Details |
|---|---|
| Japan Market Size (2033) | US$ 643.8 million |
| Japan Market Absolute Dollar Growth (US$ million/billion) | US$ 259.5 million |
The Asia Pacific currently holds a notable share of the neurological biomarkers market, with Japan and India as its most lucrative markets. This is attributed to a growing number of clinical studies being done in developing nations such as India and China, as well as rising illness rates and growing demand for targeted therapies in the central nervous system, which are projected to fuel the biomarkers market.
Japan holds a revenue share of 5.3%, with an approximated valuation of US$ 643.8 million by 2033. The country has a strong position in the neuroimaging market, owing to the launch of unique solutions such as PET scanners with motion correction and the development of new IVD tests, which are expected to catalyze the growth of the medical device industry in the country.
Japan is a country with a high number of elderly people. As the geriatric population grows, it is expected that the number of patients suffering from neurodegenerative disorders may grow as well. As the chance of getting various diseases grows with age, numerous biomarkers that could be used to evaluate diseases are being developed. These biomarkers can detect the presence of diseases as well as track their progression and treatment success.
| Attributes | Details |
|---|---|
| India Market Size (2033) | US$ 354 million |
| India Market Absolute Dollar Growth (US$ million/billion) | US$ 157.9 million |
India is currently the largest neurological biomarkers market and holds a high revenue share of 6.1%, with an approximated valuation of US$ 354 million by 2033. In India, key players strive to alter the future of healthcare by using ultrasensitive biomarker detection. A certain market player has a team of empowered researchers that use their ‘Simoa’ precision tools, diverse menu of assay kits, and bespoke assay creation services to bring breakthrough discoveries in illness and therapy to the forefront.
The digital health solutions offered by regional players enable the development of methodologies that provide illness diagnosis far earlier, improved prognoses, and enhanced treatment ways to improve the population's quality of life and lifespan for future generations.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Start-up companies are offering additional therapeutic solutions, as well as advanced technology to provide ample biomarkers in neurological disorders:
The presence of a considerable number of key companies in several regions is contributing to market growth. Ongoing research and development (R&D) activities to develop advanced technologies, as well as new product innovation, further creates numerous opportunities for the neurological biomarkers market share.
Recent Developments:
The neurological biomarkers market is predicted to grow at a CAGR of 4.6% during the forecast period.
Growing use of neurological biomarkers to identify biological and pathological systems concerning treatment strategies.
India is expected to hold a major share of the market, followed by China.
1. Executive Summary | Neurological Biomarkers Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ million) Analysis, 2017 to 2022 4.2. Current and Future Market Size Value (US$ million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ million) Analysis By Type, 2017 to 2022 5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Type, 2023 to 2033 5.3.1. Genomics Biomarker 5.3.2. Proteomics Biomarkers 5.3.3. Metabolomics Biomarkers 5.3.4. Imaging Biomarkers 5.3.5. Others 5.4. Y-o-Y Growth Trend Analysis By Type, 2017 to 2022 5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033 6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Application 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ million) Analysis By Application, 2017 to 2022 6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Application, 2023 to 2033 6.3.1. Alzheimer's Disease 6.3.2. Parkinson's Disease 6.3.3. Huntington's Disease 6.3.4. Schizophrenia 6.3.5. Depression 6.3.6. Multiple Sclerosis 6.3.7. Spinal Muscular Atrophy 6.4. Y-o-Y Growth Trend Analysis By Application, 2017 to 2022 6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ million) Analysis By End User, 2017 to 2022 7.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By End User, 2023 to 2033 7.3.1. Research Organizations, Pharma & Biotech Companies 7.3.2. Clinical Diagnostics 7.4. Y-o-Y Growth Trend Analysis By End User, 2017 to 2022 7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ million) Analysis By Region, 2017 to 2022 8.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. Asia Pacific 8.3.5. Middle East and Africa (MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2022 9.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. The USA 9.2.1.2. Canada 9.2.2. By Type 9.2.3. By Application 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Type 9.3.3. By Application 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2022 10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Argentina 10.2.1.4. Rest of Latin America 10.2.2. By Type 10.2.3. By Application 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Type 10.3.3. By Application 10.3.4. By End User 10.4. Key Takeaways 11. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2022 11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. France 11.2.1.3. The United Kingdom 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Russia 11.2.1.7. Rest of Europe 11.2.2. By Type 11.2.3. By Application 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Type 11.3.3. By Application 11.3.4. By End User 11.4. Key Takeaways 12. Asia Pacific Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2022 12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. India 12.2.1.3. Japan 12.2.1.4. Australia & New Zealand 12.2.1.5. ASEAN 12.2.1.6. Rest of Asia Pacific 12.2.2. By Type 12.2.3. By Application 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Type 12.3.3. By Application 12.3.4. By End User 12.4. Key Takeaways 13. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2022 13.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. GCC Countries 13.2.1.2. South Africa 13.2.1.3. Rest of MEA 13.2.2. By Type 13.2.3. By Application 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Type 13.3.3. By Application 13.3.4. By End User 13.4. Key Takeaways 14. Key Countries Market Analysis 14.1. The USA 14.1.1. Pricing Analysis 14.1.2. Market Share Analysis, 2022 14.1.2.1. By Type 14.1.2.2. By Application 14.1.2.3. By End User 14.2. Canada 14.2.1. Pricing Analysis 14.2.2. Market Share Analysis, 2022 14.2.2.1. By Type 14.2.2.2. By Application 14.2.2.3. By End User 14.3. Brazil 14.3.1. Pricing Analysis 14.3.2. Market Share Analysis, 2022 14.3.2.1. By Type 14.3.2.2. By Application 14.3.2.3. By End User 14.4. Mexico 14.4.1. Pricing Analysis 14.4.2. Market Share Analysis, 2022 14.4.2.1. By Type 14.4.2.2. By Application 14.4.2.3. By End User 14.5. Argentina 14.5.1. Pricing Analysis 14.5.2. Market Share Analysis, 2022 14.5.2.1. By Type 14.5.2.2. By Application 14.5.2.3. By End User 14.6. Germany 14.6.1. Pricing Analysis 14.6.2. Market Share Analysis, 2022 14.6.2.1. By Type 14.6.2.2. By Application 14.6.2.3. By End User 14.7. France 14.7.1. Pricing Analysis 14.7.2. Market Share Analysis, 2022 14.7.2.1. By Type 14.7.2.2. By Application 14.7.2.3. By End User 14.8. The United Kingdom 14.8.1. Pricing Analysis 14.8.2. Market Share Analysis, 2022 14.8.2.1. By Type 14.8.2.2. By Application 14.8.2.3. By End User 14.9. Spain 14.9.1. Pricing Analysis 14.9.2. Market Share Analysis, 2022 14.9.2.1. By Type 14.9.2.2. By Application 14.9.2.3. By End User 14.10. Italy 14.10.1. Pricing Analysis 14.10.2. Market Share Analysis, 2022 14.10.2.1. By Type 14.10.2.2. By Application 14.10.2.3. By End User 14.11. Russia 14.11.1. Pricing Analysis 14.11.2. Market Share Analysis, 2022 14.11.2.1. By Type 14.11.2.2. By Application 14.11.2.3. By End User 14.12. China 14.12.1. Pricing Analysis 14.12.2. Market Share Analysis, 2022 14.12.2.1. By Type 14.12.2.2. By Application 14.12.2.3. By End User 14.13. India 14.13.1. Pricing Analysis 14.13.2. Market Share Analysis, 2022 14.13.2.1. By Type 14.13.2.2. By Application 14.13.2.3. By End User 14.14. Japan 14.14.1. Pricing Analysis 14.14.2. Market Share Analysis, 2022 14.14.2.1. By Type 14.14.2.2. By Application 14.14.2.3. By End User 14.15. Australia & New Zealand 14.15.1. Pricing Analysis 14.15.2. Market Share Analysis, 2022 14.15.2.1. By Type 14.15.2.2. By Application 14.15.2.3. By End User 14.16. ASEAN 14.16.1. Pricing Analysis 14.16.2. Market Share Analysis, 2022 14.16.2.1. By Type 14.16.2.2. By Application 14.16.2.3. By End User 14.17. GCC Countries 14.17.1. Pricing Analysis 14.17.2. Market Share Analysis, 2022 14.17.2.1. By Type 14.17.2.2. By Application 14.17.2.3. By End User 14.18. South Africa 14.18.1. Pricing Analysis 14.18.2. Market Share Analysis, 2022 14.18.2.1. By Type 14.18.2.2. By Application 14.18.2.3. By End User 15. Market Structure Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Market Share Analysis of Top Players 15.3.1. By Regional 15.3.2. By Type 15.3.3. By Application 15.3.4. By End User 16. Competition Analysis 16.1. Competition Deep Dive 16.1.1. Quanterix 16.1.1.1. Overview 16.1.1.2. Product Portfolio 16.1.1.3. Profitability by Market Segments 16.1.1.4. Sales Footprint 16.1.1.5. Strategy Overview 16.1.1.5.1. Marketing Strategy 16.1.2. Qiagen 16.1.2.1. Overview 16.1.2.2. Product Portfolio 16.1.2.3. Profitability by Market Segments 16.1.2.4. Sales Footprint 16.1.2.5. Strategy Overview 16.1.2.5.1. Marketing Strategy 16.1.3. ADx NeuroSciences NV 16.1.3.1. Overview 16.1.3.2. Product Portfolio 16.1.3.3. Profitability by Market Segments 16.1.3.4. Sales Footprint 16.1.3.5. Strategy Overview 16.1.3.5.1. Marketing Strategy 16.1.4. Merck KGaA 16.1.4.1. Overview 16.1.4.2. Product Portfolio 16.1.4.3. Profitability by Market Segments 16.1.4.4. Sales Footprint 16.1.4.5. Strategy Overview 16.1.4.5.1. Marketing Strategy 16.1.5. Enrolmmun 16.1.5.1. Overview 16.1.5.2. Product Portfolio 16.1.5.3. Profitability by Market Segments 16.1.5.4. Sales Footprint 16.1.5.5. Strategy Overview 16.1.5.5.1. Marketing Strategy 16.1.6. Thermo Fisher Scientific 16.1.6.1. Overview 16.1.6.2. Product Portfolio 16.1.6.3. Profitability by Market Segments 16.1.6.4. Sales Footprint 16.1.6.5. Strategy Overview 16.1.6.5.1. Marketing Strategy 16.1.7. ACOBIOM 16.1.7.1. Overview 16.1.7.2. Product Portfolio 16.1.7.3. Profitability by Market Segments 16.1.7.4. Sales Footprint 16.1.7.5. Strategy Overview 16.1.7.5.1. Marketing Strategy 16.1.8. Banyan Biomarkers, Inc. 16.1.8.1. Overview 16.1.8.2. Product Portfolio 16.1.8.3. Profitability by Market Segments 16.1.8.4. Sales Footprint 16.1.8.5. Strategy Overview 16.1.8.5.1. Marketing Strategy 16.1.9. Olink Biosciences 16.1.9.1. Overview 16.1.9.2. Product Portfolio 16.1.9.3. Profitability by Market Segments 16.1.9.4. Sales Footprint 16.1.9.5. Strategy Overview 16.1.9.5.1. Marketing Strategy 16.1.10. Bio-Rad Laboratories Inc. 16.1.10.1. Overview 16.1.10.2. Product Portfolio 16.1.10.3. Profitability by Market Segments 16.1.10.4. Sales Footprint 16.1.10.5. Strategy Overview 16.1.10.5.1. Marketing Strategy 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Neurological Biomarkers Market
